Multiple Sclerosis

We’re committed to advancing the clinical understanding of underlying disease activity and progression for the thousands of people living with multiple sclerosis (MS) in New Zealand.


MS is a progressive disease. While MS can present itself differently for each person, its underlying biology is similar for everyone. No matter what form of MS a person is diagnosed with, disease progression is present from the start.

MS is an immune-mediated disease of the central nervous system and the leading cause of non-traumatic disability in young adults, affecting people in the prime of their lives. Disease progression was once only associated with secondary progressive and primary progressive MS but is now recognised in relapsing remitting MS, even if a person is not experiencing relapses.


MS and disease progression can be a complicated topic to understand. As we gain a deeper understanding of disease progression and the different ways MS can present itself inside the body, we know that it’s a disease that can be managed and should be treated as early as possible.

Our ongoing research continues to advance our understanding of MS disease progression and what lies within the highly complex brain.

There’s a symbiotic relationship between our understanding of MS and our tools for measuring it – better understanding leads to better tools, and better tools lead to a better understanding. We learn as we go, both in science and in the measurement of disease and its impact. At Roche we’re committed to advancing on both fronts.


MS community stories: Graham

Listen to Graham's story as he shares his journey living with multiple sclerosis following diagnosis at 55-years old.

More cases of Neuroscience

View detail of Neuroscience


© 2024, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.

M-NZ-00000625-v10.0/MR10379/MAY24. This site was last updated MAY2024

ContactDrug SafetyWorldwide LocationslinkedinfacebooktwitterinstagramyoutubePharma solutionsRoche careersRoche cancer treatmentsRoche diagnosticsRoche hubPrivacy statementLegal statementContact UsHealthcare Professionals Portal